The motor effects of cannabinoids in the globus pallidus appear to be caused by increases in interstitial GABA. To elucidate the mechanism of this response, we investigated the effect of the selective cannabinoid type 1 receptor (CB1) cannabinoid agonist arachidonyl-2-chloroethylamide (ACEA) on [ 3 H]GABA release in slices of the rat globus pallidus. ACEA had two effects: concentrations between 10 Ϫ8 and 10 Ϫ6 M stimulated release, whereas higher concentrations (IC 50 Ϸ 10 Ϫ6 M) inhibited it. Another cannabinoid agonist, WIN-55,212-2, also had bimodal effects on release. Studies of cAMP production indicate that under conditions of low G i/o , availability the coupling of CB1 receptors with G i/o proteins can be changed into CB1:G s/olf coupling; therefore, we determined the effects of conditions that limit G i/o availability on 
H]GABA release in slices of the rat globus pallidus. ACEA had two effects: concentrations between 10 Ϫ8 and 10 Ϫ6 M stimulated release, whereas higher concentrations (IC 50 Ϸ 10 Ϫ6 M) inhibited it. Another cannabinoid agonist, WIN-55,212-2, also had bimodal effects on release. Studies of cAMP production indicate that under conditions of low G i/o , availability the coupling of CB1 receptors with G i/o proteins can be changed into CB1:G s/olf coupling; therefore, we determined the effects of conditions that limit G i/o availability on [(1-ethyl-2-pyrrolidinyl) methyl]-2-methoxybenzamidersqb] or depleting dopamine with reserpine inhibited the ACEA-induced stimulation of release. Thus, the D2 dependence of stimulation is consistent with the proposal that D2 receptors reduce G i/o proteins available for binding to the CB1 receptor. In summary, CB1 receptor activation has dual effects on GABA release in the globus pallidus. Low concentrations stimulate release through a process that depends on activation of dopamine D2 receptors that may limit G i/o protein availability. Higher concentrations of cannabinoid inhibit GABA release through mechanisms that are independent of D2 receptor activation.
The CB1 cannabinoid receptor is one of the most abundant receptor proteins in the brain (Herkenham et al., 1991b; Mailleux and Vanderhaeghen, 1992) . This receptor, originally identified as the site of action of exogenous psychoactive substances, is the site of action of endogenous ligands produced by nerve cells, such as anandamide and 2-arachidonoyl glycerol (Romero et al., 2002) . The most widespread neuronal effect of CB1 cannabinoid agonists seems to be the inhibition of transmitter release from presynaptic terminals (Schlicker and Kathmann, 2001) . Retrograde inhibition of transmission occurs when endocannabinoids released by postsynaptic neuronal activity de- press transmitter release at presynaptic nerve endings (for references, see Maejima et al., 2001) .
CB1 receptors are expressed at high levels in the hippocampus, cortex, cerebellum, and basal ganglia (Herkenham et al., 1991b) . Within the basal ganglia, high densities of CB1 receptors are found in the globus pallidus, a structure that also contains particularly high concentrations of endocannabinoids (Di Marzo et al., 2000) . Because the globus pallidus does not contain detectable levels of CB1 mRNA (Mailleux and Vanderhaeghen, 1992) , the receptors are very likely located in terminals projecting from other nuclei. Lesions that affect striatopallidal GABAergic projections markedly reduce CB1 receptors in the globus pallidus (Herkenham et al., 1991a; Glass et al., 2000) . Furthermore, Venderova et al. (2005) found that cannabinoid receptor activation modulates GABA transporters in these terminals.
The motor and electrophysiological effects of cannabinoids in the globus pallidus are similar to those of activation of GABAergic receptors (Wickens and Pertwee, 1993; Miller and Walker, 1998) , suggesting that cannabinoids increase GABAergic transmission. Given the high density and selective location of CB1 receptors on GABAergic terminals of the globus pallidus (Mát-yás et al., 2006) , an effect on GABA release may be involved. Therefore, we examined [ 3 H]GABA release in the globus pallidus and found that, within a certain range of concentrations, activation of CB1 receptors can increase release.
We also examined the effects of restricting G i/o protein availability on [ 3 H]GABA release because studies of cAMP production (Glass and Felder, 1997; Bonhaus et al., 1998; Bash et al., 2003) show that under conditions of low G i/o availability, the usual coupling of CB1 receptors with G i/o proteins can be changed into CB1:G s/olf coupling. cAMP is a major modulator of GABA release by nerve terminals; increased cytoplasmic cAMP increases GABA release (Shindou et al., 2002) .
The role of activation of dopamine D2 receptors on the response to stimulation of CB1 receptors was also investigated because Glass and Felder (1997) have shown that stimulation of D2 receptors may reduce G i/o availability. Preliminary reports of these observations have been published in abstract form .
Materials and Methods
Slice Preparation. Slices were obtained from male Wistar rats weighing 180 to 220 g and maintained and handled according to the guidelines of the Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional Animal Care Committee. After rapid decapitation, the brain was removed and submerged in ice-cold artificial cerebrospinal fluid, which had the following composition: 118.25 mM NaCl, 1.75 mM KCl, 1 mM MgSO 4 , 1.25 mM KH 2 PO 4 , 25 mM NaHCO 3 , 2 mM CaCl 2 , and 10 mM D-glucose, gassed continuously with O 2 /CO 2 [95:5 (v/v) ] at 4°C, pH 7.4. The brain was glued with cyanoacrylate to a metal cube mounted on a Petri dish filled with ice-cold artificial cerebrospinal fluid, and coronal slices (300 m thick) containing the globus pallidus were obtained with a vibroslicer (Campden Instruments Ltd., Leicester, UK).
[ 3 H]GABA Release. Methods for measuring [ 3 H]GABA release and data analysis are described by Florá n et al. (2004) . The slices were first incubated for 30 min at 37°C in ASCF. Then, they were transferred for 30 min to an ASCF that contained 8 nM [ 3 H]GABA in 2 ml of ASCF solution containing 10 M aminooxyacetic acid (to prevent, by inhibiting GABA transaminase, degradation of the label). At the end of this period, excess radiolabel was removed by washing twice with ASCF containing, in addition to aminooxyacetic acid, 10 M nipecotic acid (to prevent the reuptake of the label). Both compounds were present in the perfusion solution for the rest of the experiment. The slices were apportioned randomly between the chambers (usually four slices per chamber) of a superfusion system (volume of each chamber, 80 l; 20 chambers in parallel) and perfused with the medium at a rate of 0.5 ml/min for 1 h. Basal release of [ 3 H]GABA was measured by collecting four fractions of the superfusate at 4-min intervals (each fraction, 2 ml) before release was stimulated by changing to a solution with 20 mM K ϩ (101.25 mM NaCl, 18.75 mM KCl, 1 mM MgSO 4 , 1.25 mM KH 2 PO 4 , 25 mM NaHCO 3 , 2 mM CaCl 2 , and 10 mM D-glucose) . Six more fractions were collected in the high-K ϩ medium. To determine the total amount of tritium remaining in the tissue, the slices were collected, treated with 1 ml of 1 M HCl, and allowed to stand for 1 h before addition of the scintillator.
[ 3 H]GABA release was expressed initially as a fraction of the total amount of tritium remaining in the tissue. The effect of drugs on the basal release of [ 3 H]GABA was assessed by comparing the fractional release in fraction 2 (immediately before exposure of the tissue to drug) and fraction 4 (immediately before exposure to 20 mM K ϩ ), using the paired Student's t test. Changes in K ϩ -evoked [ 3 H]GABA release were assessed by comparing the area under the appropriate release curves between the first and last fractions collected after the change to high K ϩ , making the assumption that the basal release of [ 3 H]GABA would remain unchanged at the level measured in the fraction immediately preceding K ϩ stimulation. In experiments in which this was tested, the basal release in fraction 10 was 98 Ϯ 4% of that in fraction 4.
To obtain an unbiased estimate of IC 50 values, concentrationresponse data for the inhibition of [ 3 H] GABA release were fitted by nonlinear regression to a hyperbola. To test for statistical differences between treatments, the area under the release curve in the presence of elevated K ϩ was calculated for each individual chamber, and the data were then analyzed by one-way analysis of variance, followed by Tukey-Kramer multiple comparison test.
Reserpinization and Pertussis Toxin Treatment. Rats were pretreated with reserpine (10 mg/kg i.p.) 18 h before preparation of slices. Control animals were treated with the same volume (1 ml/kg) of vehicle [7% (w/v) lactic acid]. This treatment reduced pallidal dopamine levels from 27.24 Ϯ 3 pg/g protein (n ϭ 5) in control rats to 2.84 Ϯ 0.27 pg/g protein (n ϭ 5) in reserpinized animals, i.e., a reduction of 90 Ϯ 2% (mean Ϯ S.E.M.). Rats were pretreated with pertussis toxin (PTX) 48 h before preparation of slices according to methods described previously (Strömberg and Bickford-Wimer, 1991) . Animals weighing 180 to 200 g were anesthetized with chloral hydrate (350 mg/kg) and mounted in a stereotaxic apparatus. A microinjection needle (22 gauge, 12 mm long) was placed in one globus pallidus (coordinates, Ϫ 0.4 and 3.0 mm lateral to bregma and Ϫ4.7 mm from dura), and a single dose of PTX (2.5 g/2.5 l at a rate of 0.2 l/min) was injected using a microsyringe pump.
Drugs. Arachidonyl-2-chloroethylamide (ACEA), WIN-55,212-2, and AM251 were purchased from Tocris Bioscience (Ellisville, MO). Amino oxyacetic acid, forskolin, 3-isobutyl-1-methylxanthine, N-ethylmaleimide (NEM), nipecotic acid, quinpirole, reserpine, and sulpiride were obtained from Sigma-Aldrich (St. Louis, MO).
Results

Effects of ACEA and WIN-55,212-2 on [
3 H]GABA Release. We determined the dose dependence of two cannabinoid agonists on [ 3 H]GABA release; one, the synthetic cannabinoid ACEA, because of its very high selectivity for CB1 receptors, and the other, the amino alkylindole WIN-55,212-2, because it is probably the most widely used of the agonists in experimental studies (Howlett et al., 2002 Effects of PTX and NEM on the Response to Stimulation to CB1 Receptors. The inhibition of cAMP synthesis produced more generally by activation of CB1 receptors is converted by PTX into a stimulation of synthesis (Glass and Felder, 1997; Bonhaus et al., 1998; Bash et al., 2003) . We examined the effects of two uncouplers of receptor-G i protein interactions, PTX and NEM (Shapiro et al., 1994) , on the ACEA-induced changes in GABA release. PTX uncouples from G i proteins by catalyzing ADP ribosylation of the ␣-subunit, thus preventing activation of G proteins (Offermanns, 2003) . NEM is a sulfhydryl alkylating agent that is used to selectively inactivate G protein-mediated inhibition in neural cells (Shapiro et al., 1994; Castro et al., 2007; Jin and Smith, 2007 ; Nava-Asbell et al., 2007).
Twenty-four hours after unilateral injection of pertussis toxin, two groups of slices were dissected from each side of the brain to test drug effects. In slices obtained from the uninjected side, the D2 receptor agonist quinpirole (10 Ϫ6 M) depressed GABA release. In the pertussis-injected side, the response to activating D2 receptors was blocked (Fig. 3A) . On the uninjected side of the brain, ACEA (10 Ϫ5 M) inhibited release as normally seen in uninjected brains (see Fig. 1 ). In contrast, in slices obtained from the pertussis-injected side, ACEA (10 Ϫ5 M) stimulated release. In slices incubated with NEM (10 Ϫ5 M), the inhibitory effects of quinpirole were blocked, whereas the inhibition, normally seen in control slices with 10 Ϫ5 M ACEA, was converted into a stimulatory response.
Dopamine Dependence of ACEA Effects. The stimulatory effects of cannabinoids on cAMP production are dependent on activation of dopamine D2 receptors (Glass and Felder, 1997) . cAMP is a major modulator of GABA release by nerve terminals; increased cytoplasmic cAMP stimulates GABA release (Shindou et al., 2002) . Therefore, we determined whether interfering with D2 receptors influenced the responses of GABA efflux to ACEA treatment.
The stimulation of GABA release caused by ACEA (10
Ϫ6
) was eliminated when slices were incubated with the D2 receptor antagonist sulpiride (10 Ϫ5 M). In contrast, the inhibitory effects of ACEA were not blocked by sulpiride (Fig. 4, A and C) . Similar results were observed when the effects of ACEA were examined in slices obtained from rats pretreated with reserpine to produce dopamine depletion; the stimulatory effects of the cannabinoid agonist were eliminated, whereas the inhibitory action persisted (Fig. 4, B and C) . The dose dependence for ACEA on the inhibitory response was similar in both groups (Fig. 4C) . The IC 50 was 3.52 M (confidence interval, 1.8 -5.42) for sulpiride-treated slices and 1.46 M (IC 50 , 1.13-11.90) for reserpine-treated animals. Maximum inhibition was 49 Ϯ 3 and 45 Ϯ 5%, respectively.
Effects of ACEA on [ 3 H]GABA Release in ForskolinTreated Slices. Glass and Felder (1997) , using forskolintreated tissues, found that individual administration of either CB1 receptor or D2 receptor agonists inhibited cAMP accumulation, whereas coactivation of these receptors prevented the inhibition. We examined whether the behavior of GABA efflux in forskolin-treated tissues paralleled the changes in cAMP accumulation described by Glass and Felder (1977) . In this part of the study, we used slices of reserpine-treated animals to prevent D2 receptor activation by endogenous dopamine.
Either ACEA (10 Ϫ6 M) or quinpirole given alone (10 Ϫ6 M) inhibited forskolin-stimulated GABA release (Fig. 5A ). Concurrent treatment with ACEA and quinpirole reversed in a concentration-dependent manner the inhibition produced by either agent alone (Fig. 5, B and C) .
Discussion
We have shown that activation of cannabinoid receptors with either ACEA or WIN-55,212-2 has a bimodal effect on depolarization-induced GABA release in the globus pallidus; low concentrations of cannabinoid stimulate, and higher concentrations inhibit, release. Blockade of receptor-G i protein interactions, with either pertussis toxin or NEM, converts the inhibition of GABA release produced by stimulating CB1 receptors into stimulation. Furthermore, preventing D2 re- ceptors activation with either sulpiride or reserpine blocked the stimulatory response.
The stimulation of release is probably the most physiologically relevant because it is seen with lower concentrations of cannabinoid. Increased GABA release would explain both the decreased firing of pallidal cells (Miller and Walker 1998) and the motor depression caused by cannabinoids acting in the globus pallidus (Wickens and Pertwee, 1993; Sañ udo-Peñ a et al., 2000) . Higher doses of ACEA inhibited GABA release. The additional effects may be related to the multiphasic motor effects observed when increasing doses of cannabinoid are given (Sañ udo-Peñ a et al., 2000) . These correlations are based on comparisons of in vivo and in vitro observations; therefore, they should be viewed with some caution.
Nature of GABA Release. K ϩ depolarization can stimulate GABA release from both nerve terminals and glial cells (Bernath, 1992) . GABA release from glial cells is stimulated only when concentrations of K ϩ higher than 50 to 60 mM are used and not Ca 2ϩ -dependent (Bernath, 1992) . In our experiments, we depolarized with only 20 mM K ϩ , and, in agreement with previous findings (Floran et al., 2005) , the response nearly disappeared when Ca 2ϩ was omitted from the solution. Such Ca 2ϩ dependence of the stimulation also implies that depolarization-induced increase in [ 3 H]GABA release is not mediated by reversed activity of the GABA transporter because release through the transporter is not Ca 2ϩ dependent (Bernath, 1992) . Moreover, similar conclusions are reached when the effects of activation of D2 receptors on GABA transmission in the globus pallidus are evaluated with either electrophysiological techniques (Cooper and Stanford 2001) or [ 3 H]GABA release determinations (Floran et al., 2005) . Thus, all the available evidence suggests that depolarization-induced GABA release, as determined in our experiments, originates largely from nerve terminals.
Two major groups of terminals can release GABA in the rat globus pallidus: the projections from striatal medium-sized spiny neurons and the intranuclear collaterals of pallidal GABAergic neurons (see Gerfen and Young 1988; Cooper and Stanford, 2001) . We suggest that modulation of GABA release by CB1 receptors occurs at the projections from striatal medium-sized spiny neurons because this cell population seems to be the only one that both expresses CB1 and D2 receptors (Hermann et al., 2002) and provides a high density of GABAergic terminals within the globus pallidum (Gerfen and Young, 1988) .
Restriction of G i/o Availability Reverses CB1-Induced Inhibition. Interference with CB1 receptor G i protein coupling converted the inhibitory effects of ACEA on transmitter release into stimulation. We used two agents that block coupling through very different mechanisms, and both had similar effects. PTX uncouples receptors from G i/o proteins by catalyzing ADP ribosylation of the ␣-subunit, thus preventing activation of G i proteins (Offermanns, 2003) . N-Ethylmaleimide is a sulfhydryl alkylating agent that is used frequently to selectively inactivate G i protein-mediated jpet.aspetjournals.org inhibition in neural cells (Shapiro et al., 1994; Castro et al., 2007; Jin and Smith, 2007; Nava-Asbell et al., 2007) .
A PTX-induced reversal of the inhibitory effects of CB1 on cAMP production has been observed previously in primary cultures of striatal neurons and in transfected Chinese hamster ovary cells (Glass and Felder, 1997; Bonhaus et al., 1998 ; Bash et al., 2003) . Based on these findings, these authors proposed that CB1 receptors can interact with either G i/o or G s/olf proteins. When G i/o proteins are widely available, they prevent coupling of the CB1 receptor to the G s protein; however, as with the G i/o , protein availability is restricted, switching from G␣ i/o to G s/olf as linkage occurs (Glass and Felder, 1997) . Our results are consistent with this interpretation. In addition, we show that these interactions are significant in the control of transmitter release, thus implying that they occur within the nerve terminal.
Activation of Dopamine D 2 Receptors Reverses CB1-Induced Inhibition. Activation of either D2 or CB1 receptors generally promotes receptor interaction with G i/o proteins (Offermanns 2003) . In contrast, Glass and Felder (1997) found that cAMP production was stimulated when D2 and CB1 receptors were coactivated. They suggested that activation of D2 receptors is necessary for the cannabinoidstimulated accumulation of cAMP because activation of D2 receptors would render G i/o proteins unavailable for binding to the activated CB1 receptor. Under these circumstances, G s proteins would bind to the CB1 receptors.
Our determinations of [ 3 H]GABA release parallel those of Glass and Felder (1997) and, therefore, are consistent with their explanation. When activation of D2 receptors was prevented by either blockade with sulpiride or depletion of endogenous dopamine with reserpine, the stimulation of GABA release produced by activation of CB1 receptors in the globus pallidus was abolished. Conversely, the inhibition of GABA release produced by activation of CB1 receptors in reserpinized slices could be reversed by addition of the D2 agonist quinpirole. Although the binding of G s/olf proteins to CB1 receptors may be modified through other processes, such as receptor-receptor interactions (Kearn et al., 2005) , the effects of PTX and NEM show that that restricting G i/o protein availability is sufficient to enable the switching to CB1/G s coupling.
Some results differ from the pattern reported by Glass and Felder (1997) . For example, Meschler and Howlett (2001) , working with synaptosomes isolated from rat and monkey brains, found that independent activation of either CB1 receptor or D2 inhibited cAMP accumulation; however, they did not find that coactivation of these receptors prevented the inhibition. Glass and Felder (1997) used primary cultures of striatal neurons and of Chinese hamster ovary cells expressing the CB1 receptor. One possibility was that the results of Glass and Felder (1997) reflected behavior peculiar to cultured cells. Our results, however, in slices of the globus pallidus shown that the interactions of CB1 and D2 receptors have consequences for GABA release in the in vitro brain.
Major differences in experimental design may contribute significantly to the discrepancies. For example, cell breakdown necessary for the isolation of synaptosomes may affect the integrity of signaling pathways. Other discrepancies have emerged when investigators have studied the effects of CB1 receptor activation on forskolin-stimulated cAMP production or GABA release in different preparations (Jarrahian et al., 2004; Köfalvi et al., 2005) . In human embryonic kidney cultures, transfected with CB1 receptors, activation of CB1 receptors in the absence of D2 receptor expression depressed forskolin-stimulated cAMP; however, the pure coexpression of D2 receptors in the same cells, without coactivation by agonists, was sufficient to reverse the CB1-induced inhibition of cAMP production (Jarrahian et al., 2004) . Moreover, in these experiments, PTX did not reverse the CB1-induced inhibition of cAMP production. Finally, Köfalvi et al. (2005) , using slices dissected from the striatum, found that CB1 receptor activation only depressed electrically stimulated release of GABA.
Inhibition of Release. We found that ACEA concentrations of 10 Ϫ5 M or higher inhibit GABA release. Inhibition was the only effect on release seen in the striatum by Köfalvi et al. (2005) or by ourselves after eliminating dopamine D2 influences. The available evidence is insufficient to explain why the response changes so drastically. A clue for a possible mechanism, however, is suggested by observations showing that the amount of cannabinoid agonist required to activate individual G proteins can vary over a 30-fold range for different G ␣ subunits (Prather et al., 2000) . This observation opens the possibility that in our experiments, different G proteins were activated as cannabinoid concentration was increased.
GABA Uptake. Some investigators have found that tetrahydrocannabinol and WIN-55,212-2 in concentrations above 
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50 M inhibit GABA uptake in the globus pallidus (Maneuf et al., 1996a,b) , whereas others report that CB1 receptor agonists do not inhibit GABA uptake in the globus pallidus (Romero et al., 1998; Venderova et al., 2005) or the striatum (Köfalvi et al., 2005) . We found (using the uptake methods described by ) that high concentrations of ACEA (between 10 Ϫ4 and 10 Ϫ3 M) inhibit GABA uptake (Gonzalez et al., 2004) . The physiological significance of these findings is difficult to understand because of the very high concentrations of agonist required.
In conclusion, CB1 receptor activation has a dual effect on depolarization-induced Ca 2ϩ -dependent GABA release in the globus pallidus. Low concentrations of agonist stimulate release through a process that depends on activation of dopamine D2 receptors, whereas higher concentrations inhibit release. The dependence of stimulation on D2 receptor stimulation, taken together with the reversal of the inhibitory effects of CB1 caused by PTX and NEM, are consistent with the proposal that the linkage of CB1 receptors with either G i/o or G s/olf proteins can be modulated.
